

1 XAVIER BECERRA
Attorney General of California
2 MARY CAIN-SIMON
Supervising Deputy Attorney General
3 JOSHUA M. TEMPLET
Deputy Attorney General
4 State Bar No. 267098
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 510-3533
6 Facsimile: (415) 703-5480
E-mail: Joshua.Templet@doj.ca.gov
7 *Attorneys for Complainant*

8 **BEFORE THE**
9 **MEDICAL BOARD OF CALIFORNIA**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

11 In the Matter of the Accusation Against:

Case No. 800-2018-042567

12 **JOHN FRANCIS MITCHELL, M.D.**
13 **555 Harrison Street**
Emmaus, PA 18049-2339

DEFAULT DECISION
AND ORDER

14 **Physician's and Surgeon's Certificate**
15 **No. G 51589**

[Gov. Code §11520]

16 Respondent

17
18 **FINDINGS OF FACT**

19 1. On August 13, 2018, Complainant Kimberly Kirchmeyer, in her official capacity as
20 the Executive Director of the Medical Board of California, Department of Consumer Affairs, filed
21 Accusation No. 800-2018-042567 (Accusation) against John Francis Mitchell, M.D.
22 (Respondent) before the Medical Board of California (Board).

23 2. On November 7, 1983, the Board issued Physician's and Surgeon's Certificate
24 No. G 51589 to Respondent. The Physician's and Surgeon's Certificate was in full force and effect
25 at all times relevant to the charges brought herein and will expire on November 30, 2018, unless
26 renewed. (Exhibit Package, Exhibit 1¹: Certificate of License.)

27
28 ¹ The evidence in support of this Default Decision and Order is separately contained in the
"Exhibit Package."

1 3. On August 13, 2018, an employee of the Board served by certified mail a copy of the
2 Accusation, Statement to Respondent, Notice of Defense, Request for Discovery, and
3 Government Code sections 11507.5, 11507.6, and 11507.7 on Respondent at his address of record
4 with the Board, which was and is 555 Harrison Street, Emmaus, PA 18049-2339. Respondent
5 signed for receipt of the certified mail. A copy of the Accusation, the related documents,
6 Declaration of Service, and certified mail receipt card are contained in Exhibit 2 of the Exhibit
7 Package. The Statement to Respondent advised Respondent that he was required to complete,
8 sign, and return a Notice of Defense within fifteen days if he desired a hearing on the charges.

9 4. Respondent did not respond to the Accusation by returning the requisite Notice of
10 Defense. On September 4, 2018, an employee of the Attorney General's Office sent Respondent a
11 courtesy Notice of Default. (Exhibit Package, Exhibit 3: Courtesy Notice of Default, proof of
12 service.) The courtesy Notice of Default was served on Respondent at his address of record. The
13 courtesy Notice of Default advised Respondent of the Accusation and provided Respondent with
14 an opportunity to request relief from default. Respondent has not filed a Notice of Defense to
15 date. As a result, Respondent has waived his right to a hearing on the merits to contest the
16 allegations contained in the Accusation.

17 5. The allegations of the Accusation are true as follows:

18 On February 6, 2018, the Pennsylvania State Board of Medicine ("Pennsylvania Board")
19 adopted a Consent Agreement between it and Respondent (Exhibit Package, Exhibit A to Exhibit
20 1). The Consent Agreement sets forth allegations regarding Respondent's psychiatric treatment of
21 five patients. The Consent Agreement provides that Respondent admits all of the allegations are
22 true. Among the allegations admitted by Respondent as true are the following:

23 A. Respondent treated patient FC from on or about January 18, 2013 until in or about
24 June 2014. Without documenting in the patient's medical record reasons supporting
25 his diagnoses of the patient or reasons to begin prescribing controlled substances,
26 Respondent prescribed controlled substances to FC including but not limited to 70
27
28

1 mg of Vyvanse² twice per day. By prescribing 140 mg of Vyvanse per day,
2 Respondent was exceeding the 70 mg maximum daily dose indicated by the
3 manufacturer in its FDA labeling.

4 B. Respondent treated patient PC from on or about November 2012 until in or about
5 2016. Without documenting in the patient's medical record reasons supporting his
6 diagnoses of the patient or reasons to begin prescribing controlled substances,
7 Respondent prescribed controlled substances to PC, including but not limited to 70
8 mg of Vyvanse twice per day and later 70 mg of Vyvanse three times per day. By
9 prescribing 140 mg per day of Vyvanse and and later 210 mg per day, Respondent
10 was exceeding the 70 mg maximum daily dose indicated by the manufacturer in its
11 FDA labeling.

12 C. Respondent treated patient RK from on or about January 2011 until on or about
13 October 2015. Without documenting in the patient's medical record reasons
14 supporting his diagnoses of the patient or reasons to begin prescribing controlled
15 substances, Respondent prescribed RK 70 mg of Vyvanse twice per day and later 280
16 mg of Vyvanse per day. By prescribing 140 mg of Vyvanse per day and later 280 mg
17 per day, Respondent was exceeding the 70 mg maximum daily dose indicated by the
18 manufacturer in its FDA labeling.

19 D. Respondent treated patient AK from on or about November 2005 through 2015.
20 Without documenting in the patient's medical record reasons supporting his
21 diagnoses of the patient or reasons to begin prescribing controlled substances,
22 Respondent prescribed controlled substances to AK, including but not limited to 280
23 mg of Vyvanse per day. Respondent's prescribed doses exceeded the 70 mg
24 maximum daily dose indicated by the manufacturer in its FDA labeling.

25
26
27 ² Vyvanse is the trade name of lisdexamfetamine, a central nervous system stimulant. As
28 of June 4, 2007, the Drug Enforcement Administration has classified lisdexamfetamine within
schedule II of the Controlled Substances Act. Lisdexamfetamine is marketed as a prescription
drug for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

1 E. Respondent treated patient LP five times between 2007 through 2011, and began
2 seeing the patient on a regular basis in 2013. Respondent initially prescribed this
3 patient 50 mg per day of Vyvanse. Without documenting a reason for increasing the
4 patient's dose, Respondent increased the dose initially to 100 mg per day, and later to
5 150 mg per day, 180 mg per day, and finally 240 mg per day. Respondent's
6 prescribed doses exceeded the 70 mg maximum daily dose indicated by the
7 manufacturer in its FDA labeling.

8 6. As to each of these patients, Respondent maintained insufficient or inadequate
9 documentation of the following:

- 10 • “documentation, justification, testing, counseling to the patient, as well as informed consent
11 for the medications being prescribed including but not limited to the off label Vyvanse
12 and its risks and benefits”;
- 13 • “vital signs or other physical examination, objection symptoms, reevaluation of [each
14 patient's] condition that would justify the medications being prescribed”; and
- 15 • “documentation as to whether the medications prescribed were effective, the risks and
16 benefits of prescribing said medications, whether consultation or referral to other treating
17 physicians/specialists was considered; or whether blood-alcohol or similar testing or pill
18 counts were being performed to confirm that [each patient] was not multi-sourcing
19 medications from other providers, using street drugs or alcohol.”

20 7. Respondent also prescribed other controlled substances to these patients “without
21 documentation in the medical records that would explain or justify the use of said medications.”

22 8. Based on the allegations admitted by Respondent, the Consent Agreement imposed
23 discipline, restrictions, and limitations on Respondent's practice of medicine in Pennsylvania
24 including a \$3,500 assessment for the cost of investigation and required completion of remedial
25 education courses in controlled substance prescribing, medical documentation, and ethics and
26 professionalism.

ORDER

IT IS SO ORDERED that Physician's and Surgeon's Certificate No. G 51589, heretofore issued to Respondent John Francis Mitchell, M.D., is revoked.


Respondent shall not be deprived of making a request for relief from default as set forth in Government Code section 11520, subdivision (c), for good cause shown. However, such showing must be made in writing by way of a motion to vacate the default decision and directed to the Medical Board of California at 2005 Evergreen Street, Suite 1200, Sacramento, CA 95815 within seven (7) days after service of the Decision on Respondent.

This Decision shall become effective on November 21, 2018, at 5:00p.m.

It is so ORDERED October 24, 2018

MEDICAL BOARD OF CALIFORNIA
DEPARTMENT OF CONSUMER AFFAIRS
STATE OF CALIFORNIA

By



KIMBERLY KIRCHMEYER
EXECUTIVE DIRECTOR

SF2018200742
21241056.docx

1 XAVIER BECERRA
Attorney General of California
2 MARY CAIN-SIMON
Supervising Deputy Attorney General
3 JOSHUA M. TEMPLET
Deputy Attorney General
4 State Bar No. 267098
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 510-3533
6 Facsimile: (415) 703-5480
E-mail: Joshua.Templet@doj.ca.gov
7 *Attorneys for Complainant*

FILED
STATE OF CALIFORNIA
MEDICAL BOARD OF CALIFORNIA
SACRAMENTO AUG. 13, 2018
BY [Signature] ANALYST

8 **BEFORE THE**
9 **MEDICAL BOARD OF CALIFORNIA**
10 **DEPARTMENT OF CONSUMER AFFAIRS**
11 **STATE OF CALIFORNIA**

12 In the Matter of the Accusation Against:

Case No. 800-2018-042567

13 **John Francis Mitchell, M.D.**
14 **555 Harrison Street**
15 **Emmaus, PA 18049-2339**

ACCUSATION

16 **Physician's and Surgeon's Certificate**
17 **No. G 51589,**

Respondent.

18 Complainant alleges:

19 **PARTIES**

20 1. Kimberly Kirchmeyer (Complainant) brings this Accusation solely in her official
21 capacity as the Executive Director of the Medical Board of California, Department of Consumer
22 Affairs (Board).

23 2. On or about November 7, 1983, the Medical Board issued Physician's and Surgeon's
24 Certificate Number G 51589 to John Francis Mitchell, M.D. (Respondent). The certificate was in
25 full force and effect at all times relevant to the charges brought herein and will expire on
26 November 30, 2018, unless renewed.

27 ///

28 ///

1 psychiatric treatment of five patients. The Consent Agreement provides that Respondent admits
2 all of the allegations are true. Among the allegations admitted by Respondent as true are the
3 following:

4 A. Respondent treated patient FC from on or about January 18, 2013 until in or about
5 June 2014. Without documenting in the patient's medical record reasons supporting
6 his diagnoses of the patient or reasons to begin prescribing controlled substances,
7 Respondent prescribed controlled substances to FC including but not limited to 70
8 mg of Vyvanse¹ twice per day. By prescribing 140 mg of Vyvanse per day,
9 Respondent was exceeding the 70 mg maximum daily dose indicated by the
10 manufacturer in its FDA labeling.

11 B. Respondent treated patient PC from on or about November 2012 until in or about
12 2016. Without documenting in the patient's medical record reasons supporting his
13 diagnoses of the patient or reasons to begin prescribing controlled substances,
14 Respondent prescribed controlled substances to PC, including but not limited to 70
15 mg of Vyvanse twice per day and later 70 mg of Vyvanse three times per day. By
16 prescribing 140 mg per day of Vyvanse and later 210 mg per day, Respondent was
17 exceeding the 70 mg maximum daily dose indicated by the manufacturer in its FDA
18 labeling.

19 C. Respondent treated patient RK from on or about January 2011 until on or about
20 October 2015. Without documenting in the patient's medical record reasons
21 supporting his diagnoses of the patient or reasons to begin prescribing controlled
22 substances, Respondent prescribed RK 70 mg of Vyvanse twice per day and later 280
23 mg of Vyvanse per day. By prescribing 140 mg of Vyvanse per day and later 280 mg
24 per day, Respondent was exceeding the 70 mg maximum daily dose indicated by the
25 manufacturer in its FDA labeling.

26
27 ¹ Vyvanse is the trade name of lisdexamfetamine, a central nervous system stimulant. As
28 of June 4, 2007, the Drug Enforcement Administration has classified lisdexamfetamine within
schedule II of the Controlled Substances Act. Lisdexamfetamine is marketed as a prescription
drug for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

1 D. Respondent treated patient AK from on or about November 2005 through 2015.
2 Without documenting in the patient's medical record reasons supporting his
3 diagnoses of the patient or reasons to begin prescribing controlled substances,
4 Respondent prescribed controlled substances to AK, including but not limited to 280
5 mg of Vyvanse per day. Respondent's prescribed doses exceeded the 70 mg
6 maximum daily dose indicated by the manufacturer in its FDA labeling.

7 E. Respondent treated patient LP five times between 2007 through 2011, and began
8 seeing the patient on a regular basis in 2013. Respondent initially prescribed this
9 patient 50 mg per day of Vyvanse. Without documenting a reason for increasing the
10 patient's dose, Respondent increased the dose initially to 100 mg per day, and later to
11 150 mg per day, 180 mg per day, and finally 240 mg per day. Respondent's
12 prescribed doses exceeded the 70 mg maximum daily dose indicated by the
13 manufacturer in its FDA labeling.

14 9. As to each of these patients, Respondent maintained insufficient or inadequate
15 documentation of the following:

- 16 • "documentation, justification, testing, counseling to the patient, as well as informed consent
17 for the medications being prescribed including but not limited to the off label Vyvanse
18 and its risks and benefits";
- 19 • "vital signs or other physical examination, objection symptoms, reevaluation of [each
20 patient's] condition that would justify the medications being prescribed"; and
- 21 • "documentation as to whether the medications prescribed were effective, the risks and
22 benefits of prescribing said medications, whether consultation or referral to other treating
23 physicians/specialists was considered; or whether blood-alcohol or similar testing or pill
24 counts were being performed to confirm that [each patient] was not multi-sourcing
25 medications from other providers, using street drugs or alcohol."

26 10. Respondent also prescribed other controlled substances to these patients "without
27 documentation in the medical records that would explain or justify the use of said medications."


28 ///

PRAYER

WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged, and that following the hearing, the Board issue a decision:

1. Revoking or suspending Physician's and Surgeon's Certificate Number G 51589, issued to Respondent;
2. Revoking, suspending or denying approval of Respondent's authority to supervise physician assistants and advanced practice nurses;
3. Ordering Respondent, if placed on probation, to pay the Board the costs of probation monitoring; and
4. Taking such other and further action as deemed necessary and proper.

DATED: August 13, 2018



KIMBERLY KIRCHMEYER
Executive Director
Medical Board of California
Department of Consumer Affairs
State of California
Complainant

SF2018200742
13166203.docx

EXHIBIT A

COMMONWEALTH OF PENNSYLVANIA
DEPARTMENT OF STATE
BEFORE THE STATE BOARD OF MEDICINE

PROTHONOTARY
2018 FEB -9 AM 10: 58
Department of State

Commonwealth of Pennsylvania
Bureau of Professional and
Occupational Affairs

File Nos.: 15-49-03582
15-49-14986

vs.

John Francis Mitchell, M.D.,
Respondent

Docket
No: 2257-49-17

CONSENT AGREEMENT AND ORDER

PARTIES

1. The Commonwealth of Pennsylvania, Department of State, Bureau of Professional and Occupational Affairs ("Commonwealth") and John Francis Mitchell, M.D. ("Respondent") stipulate as follows in settlement of the above-captioned case.

APPLICABLE LAW

2. This matter is before the State Board of Medicine ("Board") pursuant to the Medical Practice Act, Act of December 20, 1985, P.L. 457, No. 112, ("Act"), as amended, 63 P.S. §§ 422.1-422.53; the Medical Care Availability and Reduction of Error ("Mcare") Act, Act of March 20, 2002, P.L. 154, No. 13, as amended, 40 P.S. §§ 1303.101-1303.910; and/or the Act of July 2, 1993, P.L. 345, No. 48 ("ACT 48"), as amended, 63 P.S. §§ 2201-2207.

LICENSURE STATUS

3. At all relevant and material times, Respondent held the following license to practice as a medical physician and surgeon in the Commonwealth of Pennsylvania: license no. MD020824E, which was originally issued on July 1, 1978, and which is currently set to expire on December 31, 2018.

STIPULATED FACTS

4. The Respondent admits that the following allegations are true:

a. Absent further Board action, Respondent's license may be renewed, reactivated or reinstated thereafter upon the filing of the appropriate documentation and payment of the necessary fees.

b. Respondent's last known office address, as on file with the Board is:
1605 N Cedar Crest Blvd. Suite 502, Allentown Pa 18104.

c. At all times relevant herein, Respondent provided office psychiatric pharmacotherapy to five patients: FC, PC, RK, AK and LP.

d. At all times relevant herein, Respondent provided Vyvanse to these five patients at greater than the maximum 70 mg dose as recommended by the manufacturer in their Food and Drug Administration (FDA) labeling.

e. Respondent's use of Vyvanse with respect to these five patients was accompanied by simultaneous prescriptions for other similar medications without documentation in the medical records that would explain or justify the use of said medications.

PATIENT FC

f. From on or about January 18, 2013 until in or about June 2014, Respondent provided treatment to male patient FC, date of birth March 24, 1991.

g. According to Respondent's medical records, FC suffered from depression, anxiety, seasonal allergies, and stress from his parents' ongoing divorce; however, there is no documentation in the medical record to support these diagnoses.

h. Without documenting reasons in the medical record to support his diagnoses and the reasons to begin prescribing controlled medications, Respondent immediately began prescribing twice daily Clonazepam, 2 mg, and Vyvanse, 70 mg as well as caution legend drug Cymbalta, 60 mg

i. By prescribing Vyvanse at 140 mg/day, to FC, Respondent was exceeding the typical 70 mg maximum daily dose indicated by the manufacturer in their FDA labeling.

j. The medical record maintained by Respondent for FC had insufficient or inadequate documentation of the following:

- documentation, justification, testing, counseling to the patient, as well as informed consent for the medications being prescribed including but not limited to the off label Vyvanse and its risks and benefits;
- vital signs or other physical examination, objective symptoms, and/or re-evaluation of FC's condition that would justify the medications being prescribed including but not limited to the off label Vyvanse
- documentation as to whether the medication prescribed was effective, the risks and benefits of prescribing said medication, or whether consultation or referral to other treating physicians/specialists was considered; or whether blood-alcohol or similar testing, laboratory drug testing or pill counts were being

performed to confirm that FC was not multi-sourcing medications from other providers, using street drugs or alcohol.

PATIENT PC

k. From on or about November 2012 until in or about 2016, Respondent treated PC, a male patient with a date of birth of May 14, 1990.

l. According to Respondent's medical records, PC suffered from "ADD," (Attention Deficit Disorder), bipolar with recurring depression, restlessness, fatigue and binge eating; however, there is no documentation in the medical record to support these diagnoses.

m. Without documenting reasons in the medical record to support his diagnoses and the reasons to begin prescribing medications to PC, Respondent immediately began prescribing a variety of medications including controlled substances Adderall Extended Release, 30 mg in morning and Adderall Immediate Release, 10 mg in the evening and Lunesta, 3 mg as well as caution legend drug Lamotrigine, 25 mg.

n. At PC's second visit, without documenting reasons in the medical records, Respondent continued prescribing Adderall and Lamotrigine but added two additional controlled substances: Provigil, 200 mg and Trazadone (Restoril), 150 mg. and on PC's third visit, without documenting reasons in the medical records prescribed an additional controlled substance, Xanax, 0.5 mg to PC.

o. Over the next several months, without documenting reasons in the medical record Respondent increased the dosages of Xanax and Adderall for PC.

p. In 2014, Respondent began to simultaneously prescribe two additional controlled substances to PC: Dexedrine 20 mg a day and Vyvanse, 70 mg twice a day (140 mg); the Vyvanse prescribed which was two times the typical maximum daily dose indicated by the manufacturer in their FDA labeling.

q. In 2015, Respondent also began prescribing Prozac, a caution legend drug and increased the Vyvanse dosage to 70 mg, three times per day (210 mg), which was three times the 70 mg typical daily dose indicated by the manufacturer in their FDA labeling.

r. The medical record maintained by Respondent for PC had insufficient or inadequate documentation of the following:

- documentation, justification, testing, counseling to the patient, as well as informed consent for the medications being prescribed including but not limited to the off label Vyvanse and its risks and benefits;
- vital signs or other physical examination, objective symptoms, and/or re-evaluation of PC's condition that would justify the medications being prescribed, including but not limited to, the off label Vyvanse;
- documentation as to whether the medication prescribed was effective, the risks and benefits of prescribing said medications, or whether consultation or referral to other treating specialists was considered; or whether blood-alcohol or similar testing, laboratory drug testing or pill counts were being performed to confirm that

PC was not multi-sourcing medications from other providers using street drugs or alcohol.

PATIENT RK

s. From on or about January 2011 until on or about October 2015, Respondent provided treatment to male patient RK, date of birth August 2, 1960.

t. According to Respondent's medical records, RK suffered from "ADHD" (Attention Deficit Hyperactivity Disorder), IED (Intermittent Explosive Disorder); however, there is no documentation and/or testing in the medical record to support these diagnoses.

u. In 2011, without documenting reasons for the medication or dosage, Respondent began prescribing to RK, Vyvanse 70 mg twice daily, which is two times greater than the typical 70 mg daily dose indicated by the manufacturer in their FDA labeling, and then later, once again without documenting reasons, increased the Vyvanse to 280 mg per day, which is four times greater than the typical 70 mg dose indicated by the manufacturer in their FDA labeling.

v. The medical record maintained by Respondent for RK had insufficient or inadequate documentation of the following:

- Documentation, justification, testing, counseling to the patient, as well as informed consent for the medications being prescribed including but not limited to the off label Vyvanse and its risks and benefits;

- Vital signs or other physical examination, objective symptoms, re-evaluation of RK's condition that would justify the medications being prescribed, including but not limited, to the off label Vyvanse;

Documentation as to whether the medication prescribed was effective, the risks and benefits of prescribing said medications, or whether consultation or referral to other treating physicians/specialists was considered; or whether blood-alcohol or similar testing, laboratory drug testing or pill counts were being performed to confirm that RK was not multi-sourcing medications from other providers, using street drugs or alcohol.

PATIENT AK

w. From on or about November 2005 and continuing through 2015 Respondent provided treatment to female patient AK, date of birth July 10, 1971.

x. According to Respondent's medical records, AK suffered from bipolar disorder, insomnia, personality disorder, eating disorder chronic fatigue syndrome, and had a family history of alcoholism in her mother; however, there is no documentation in the record to support these diagnoses.

y. Without documenting justification for said medications, Respondent simultaneously prescribed sedative hypnotic medications and/or would change the dosages of the medications including but not limited to Xanax, Ambien, as well as Vyvanse which was prescribed at a rate of 280 mg per day, which is four times greater than the typical maximum daily dose of 70 mg as indicated by the manufacturer in their FDA labeling.

z. Without documenting reasons in the medical record, Respondent would switch to other medications, including but not limited to, Diazepam, Dexedrine, Zolpidem, Temazepam, Klonopin, Clonazepam and Valium as well as caution legend drugs such as Abilify, Risperidone and Seroquel.

aa. The medical record maintained by Respondent for AK had insufficient or inadequate documentation of the following:

- documentation, justification, testing, counseling to the patient, as well as informed consent for the medications being prescribed including but not limited to the off label Vyvanse and its risks and benefits;
- vital signs or other physical examination, objective symptoms, reevaluation of AK's condition that would justify the medications being prescribed including the off label Vyvanse;
- documentation as to whether the medications prescribed were effective, the risks and benefits of prescribing said medications, whether consultation or referral to other treating physicians/specialists was considered; or whether blood-alcohol or similar testing or pill counts were being performed to confirm that AK was not multi-sourcing medications from other providers, using street drugs or alcohol.

PATIENT LP

bb. From in or about 2007 through 2011, LP, a male patient, date of birth, July 16, 1951, saw Respondent five times; commencing in 2013 Respondent began seeing LP as a patient on a regular basis.

cc. According to Respondent's medical record, it appears LP suffered from Bipolar Disorder, Autism, as well as neck and back pain; however, there is no documentation in the medical record to support these diagnoses.

dd. Respondent initially prescribed Vyvanse at 50 mg, once per day but without documenting reasons in the medical record doubled the dose to 50 mg twice per day, which is more than the typical maximum daily dose of 70 mg as indicated by the manufacturer in FDA labeling.

ee. On June 24, 2013, without documenting reasons in the medical record, Respondent tripled LP's Vyvanse dosage to 50 mg three times a day, or 150 mg per day, which is more than twice the typical maximum daily dose of 70 mg per day as indicated by the manufacturer in FDA labeling.

ff. On June 29, 2013, without documenting reasons in the medical record, Respondent later increased LP's Vyvanse to 60 mg three times per day, or 180 mg, and then again in December 2013 to 60 mg, four times a day, or 240 mg, which is significantly more the 70-mg typical maximum daily dose as indicated by the manufacturer in FDA labeling.

gg. The medical record maintained by Respondent for LP had insufficient or inadequate documentation of the following;

- documentation, justification, testing, counseling to, LP that would justify the medications being prescribed as well as informed consent for the medications being prescribed including but not limited to the off label Vyvanse and its risks and benefits;
- vital signs or other physical examination, objective symptoms, reevaluation of LP's that would justify medications being prescribed including but not limited to the off label Vyvanse;

- documentation as to whether the medication prescribed was effective, the risks and benefits of prescribing said medications, or whether consultation or referral to other treating physicians/specialists was considered; or whether blood-alcohol or similar testing laboratory drug testing or pill counts were being performed to confirm that LP was not multi-sourcing medications from other providers, using street drugs or alcohol.

ALLEGED VIOLATIONS

5. The Commonwealth alleges that the Board is authorized to suspend, revoke, or otherwise restrict Respondent's license under Sections 41 and 42 of the Act, 63 P.S. §§ 422.41 & 422.42; and/or impose a civil penalty upon Respondent under Sections 39 through 42 of the Act, 63 P.S. §§ 422.39-422.42, and /or Section 5(b)(4) of ACT 48, 63 P.S. § 2205(b)(4); and/or impose the costs of investigation upon Respondent under Section 5(b)(5) of ACT 48, 63 P.S. § 2205(b)(5), because Respondent violated the Act at:

a. 63 P.S. § 422.41(6) and the Board's regulations at 49 Pa Code §16.61 in that Respondent failed to comply with the Board's regulations when prescribing controlled substances to his patients; and

b. 63 P.S. § 422.41(8) in that Respondent was guilty of immoral and unprofessional conduct with respect to his prescribing of Vyvanse at dosages greater than manufacturer's recommendations and prescribing Vyvanse together with simultaneous prescriptions for other similar medications without adequate documentation in the medical record to justify the use of said medications.

PROPOSED ORDER

6. The parties, intending to be legally bound, consent to the issuance of the following

Order in settlement of this matter:

a. The Board finds that it is authorized to suspend, revoke, or otherwise restrict Respondent's license under Sections 41 and 42 of the Act, 63 P.S. §§ 422.41 & 422.42; and/or impose a civil penalty upon Respondent under Sections 39 through 42 of the Act, 63 P.S. §§ 422.39-422.42, and/or Section 5(b)(4) of ACT 48, 63 P.S. § 2205(b)(4); and/or impose the costs of investigation upon Respondent under Section 5(b)(5) of ACT 48, 63 P.S. § 2205(b)(5), because Respondent violated the Act at:

- (1) 63 P.S. §422.41(6) and the Board's regulations at 49 Pa. Code §16.61 in that Respondent failed to comply with the Board's regulations when prescribing controlled substances to patients; and
- (2) 63 P.S. §422.41(8) in that Respondent was guilty of immoral and/or unprofessional conduct with respect to his prescribing Vyvanse at dosages greater than manufacturer's recommendations and prescribing Vyvanse together with simultaneous prescriptions for other similar medications without adequate documentation in the medical record to justify the use of said medications.

COSTS OF INVESTIGATION

b. An assessment for the **COSTS OF INVESTIGATION** of three thousand five hundred dollars (\$3500.00) is levied upon Respondent. The full sum of the costs of investigation of three thousand five hundred dollars (\$3500.00) shall be tendered by Respondent with this executed Consent Agreement and shall be paid by certified check, cashier's check, attorney's check, or money order issued by a usual, customary, and reputable issuer (e.g. U.S. Postal Money Order, Western Union Money Order, etc).

Payment shall be made payable to the "Commonwealth of Pennsylvania" and shall be valid for a period of at least one hundred eighty (180) days. Respondent agrees that payment shall only be made by one of the methods indicated above and shall not be made by uncertified personal or corporate check.

REMEDIAL EDUCATION

c. Respondent shall attend and successfully complete thirty (30) hours in intensive courses in controlled substance prescribing; medical documentation and ethics and professionalism within six months of the date of this Order. The intensive courses shall be offered by a program approved by the Board. Respondent shall seek Board approval prior to taking said courses.

d. Respondent shall also comply with all the following terms and conditions pertaining to completion of the remedial education hours:

- (1) Credits specified in this Order shall be subject to the approval of the Board and in compliance with either the initial education or the continuing education regulations of the Board;
- (2) To the extent that the remedial education courses require Respondent to pass an examination for Respondent to be eligible for initial or continuing education credits, Respondent must take and successfully pass such examination for the remedial education courses to satisfy the requirement of this Order.
- (3) Respondent shall submit acceptable proof of successful completion of the remedial professional education courses to the Board's Board Administrator within six months of the date of this Order. Respondent shall note the file number and docket number of this matter on any

documentation submitted to the Board Administrator. The address for the Board's Administrator is:

Suzanne Zerbe
State Board of Medicine
2601 N 3rd Street
P.O. Box 2649
Harrisburg, PA 17105-2649

- (4) Acceptable Proof of completion of the thirty (30) additional hours of remedial education shall consist of an official school transcript, a certificate or letter of completion prepared by the sponsor of the remedial education course or a printout prepared by the sponsor indicating the completed courses. Proof shall contain course titles, completion dates, final grade (if course is graded), and number of class hours or continuing professional education (CPE) credits awarded. Acceptable proof shall not consist of receipts, course outlines or agendas, cancelled checks, payment acknowledgments, or self-prepared records, among other documents.
- (5) Respondent shall authorize the course provider to send a course assessment to the Board's Board Administrator;
- (6) The additional hours of remedial education in this Order shall be completed in addition to the hours that Respondent shall take in this or subsequent reporting periods for the renewal of his license. Credit hours required in this Order may not be used from any previous reporting period, nor may they be used in any subsequent biennial period for the renewal of Respondent's license to practice as

a medical physician and surgeon. Respondent may not use credit hours required in this Order for purposes of satisfying any initial or continuing education requirement of any other authorization to practice the profession.

(7) Pending payment of costs of investigation and successful completion of the remedial education requirements outlined herein Respondent will have an unrestricted license which will remain unrestricted upon successful completion of the terms of this Consent Agreement.

FAILURE TO TIMELY AND SUCCESSFULLY COMPLETE THE REMEDIAL EDUCATION AS REQUIRED BY CONSENT AGREEMENT AND ORDER

e. If the Respondent fails to submit acceptable proof of successful completion of the Remedial Education within the time frame set forth in this Consent Agreement and Order, Respondent's license to practice as a medical physician and surgeon and any and all authorizations to practice the profession issued by the Board and held by Respondent shall be **IMMEDIATELY AND INDEFINITELY SUSPENDED** until such time as Respondent does provide the Board's Board Administrator with acceptable proof of successful completion of the Remedial Education as required by this Consent Agreement.

f. This Order constitutes disciplinary action by the Board and shall be reported to other licensing authorities and any applicable national licensing databank as a disciplinary action by the Board.

g. This case shall be deemed settled and discontinued upon the Board issuing an Order adopting this Consent Agreement.

ADMISSIBILITY OF CONSENT AGREEMENT IN FUTURE PROCEEDINGS

7. Respondent agrees that if Respondent is charged with a violation of an Act enforced by this Board in the future, this Consent Agreement and Order shall be admitted into evidence without objection in that proceeding.

ACKNOWLEDGMENT OF NOTICE AND WAIVER OF HEARING

8. Respondent acknowledges receipt of an Order to Show Cause in this matter. Respondent knowingly and voluntarily waives the right to an administrative hearing in this matter, and knowingly and voluntarily waives the following rights related to that hearing: to be represented by counsel at the hearing; to present witnesses and testimony in defense or in mitigation of any sanction that may be imposed for a violation; to cross-examine witnesses and to challenge evidence presented by the Commonwealth; to present legal arguments by means of a brief; and to take an appeal from any final adverse decision.

ACKNOWLEDGMENT OF RIGHT TO ATTORNEY

9. Respondent acknowledges that he is aware that he has the right to consult with, and/or be represented by, private legal counsel of Respondent's choosing and at Respondent's expense when reviewing, considering and accepting the terms of this Consent Agreement. To the extent that Respondent is not represented by legal counsel, Respondent has knowingly elected to proceed without the assistance of legal counsel.

WAIVER OF CLAIM OF COMMINGLING AND OTHER CONSTITUTIONAL CLAIMS

10. Respondent expressly waives any constitutional rights and issues, such as commingling of prosecutorial and adjudicative functions by the Board or its counsel, which may arise or have arisen during the negotiation, preparation and/or presentation of this Consent Agreement. Respondent specifically agrees that if the Board rejects this agreement, it may assume that the facts and averments as alleged in this Consent Agreement are true and correct for

the limited purpose of recommending a sanction, based on those assumed facts, that would be acceptable to the Board before hearing the case. In the event that the Board does assume the facts and averments as alleged in this Consent Agreement are true for purposes of making a recommendation as to an acceptable sanction, such action shall not constitute commingling of prosecutorial and adjudicative functions by the Board or its counsel, and the Respondent expressly waives any constitutional rights and issues related to alleged commingling, bias, or violation of due process rights to have an unbiased and impartial adjudicator in any subsequent hearing. If a hearing is subsequently held, neither this Consent Agreement nor the proposed terms of settlement may be admitted into evidence and any facts, averments, and allegations contained in the Consent Agreement must be proven at hearing unless otherwise separately stipulated. This paragraph is binding on the participants even if the Board does not approve this Consent Agreement.

NO MODIFICATION OF ORDER

11. Respondent agrees, as a condition of entering into this Consent Agreement, not to seek modification at a later date of the Stipulated Order adopting and implementing this Consent Agreement without first obtaining the express written concurrence of the Prosecution Division.

AGREEMENT NOT BINDING ON OTHER PARTIES

12. The Office of General Counsel has approved this Consent Agreement as to form and legality; however, this Consent Agreement shall have no legal effect unless and until the Board issues the stipulated Order.

EFFECT OF BOARD'S REJECTION OF CONSENT AGREEMENT

13. Should the Board not approve this Consent Agreement, presentation to and consideration of this Consent Agreement and other documents and matters by the Board shall not prejudice the Board or any of its members from further participation in the adjudication of this

matter. This paragraph is binding on the participants even if the Board does not approve this Consent Agreement.

ENTIRE AGREEMENT


14. This agreement contains the whole agreement between the participants; provided however, that the captions printed in the various provisions of this agreement are for ease of reading only and are not to be interpreted as forming any part of this agreement. There are no other terms, obligations, covenants, representations, statements or conditions, or otherwise, of any kind whatsoever concerning this agreement.

AGREEMENT DOES NOT PREVENT ADDITIONAL DISCIPLINE BASED ON OTHER COMPLAINTS


15. Nothing in this Order shall preclude the Prosecution Division for the Commonwealth from filing charges or the Board from imposing disciplinary or corrective measures for violations or facts not contained in this Consent Agreement;


VERIFICATION OF FACTS AND STATEMENTS

16. Respondent verifies that the facts and statements set forth in this Consent Agreement are true and correct to the best of Respondent's knowledge, information and belief. Respondent understands that statements in this Consent Agreement are made subject to the criminal penalties of 18 Pa.C.S.A. §4904 relating to unsworn falsification to authorities.


Anita P. Shekletski
Senior Prosecutor in Charge

DATED: 1/23/18


John Francis Mitchell, M.D.
Respondent

DATED: 1-22-2018

Todd S. Miller, Esquire
Attorney for Respondent

COMMONWEALTH OF PENNSYLVANIA
DEPARTMENT OF STATE
BEFORE THE STATE BOARD OF MEDICINE

Commonwealth of Pennsylvania
Bureau of Professional and
Occupational Affairs

File Nos.: 15-49-03582
15-49-14986

vs.

John Francis Mitchell, M.D.,
Respondent

Docket
No: 2257-49-17

ORDER

AND NOW, this 9th day of February 2018, the STATE BOARD OF MEDICINE
("Board") adopts and approves the foregoing Consent Agreement and incorporates the terms of
paragraph 6, which shall constitute the Board's Order and is now issued in resolution of this
matter.

This Order shall take effect immediately.

BUREAU OF PROFESSIONAL
AND OCCUPATIONAL AFFAIRS

Ian J. Harlow
Commissioner

For the Commonwealth:

Respondent's Counsel:

BY ORDER:
STATE BOARD OF MEDICINE

Bruce A. Brod, M.D.
Chair

Anita P. Shekletski, Esquire
2601 North Third Street
P.O. Box 69521
Harrisburg, PA 17106-9521

Todd S. Miller, Esquire
611 North Nineteenth Street
Allentown, PA 18104

DATE OF MAILING: February 9, 2018